M2Gen

AbbVie joins ORIEN Avatar Research Program

Wednesday, March 29, 2017

AbbVie, a global biopharmaceutical company, and M2Gen, a health informatics solutions company, announced that AbbVie has joined the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program. Launched in April of 2016, the ORIEN Avatar Research Program fosters collaboration among key stakeholders in cancer research with the shared goal of discovering and developing novel therapies in clinical trials.

[Read More]

Takeda, M2Gen to generate broad genomic data from consenting cancer patients

Monday, June 20, 2016

Takeda Pharmaceutical and M2Gen, a healthcare informatics solutions company, have established a new collaboration to generate broad genomic data from consenting cancer patients. Under the agreement, Takeda will help build the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program based on the Total Cancer Care Protocol, a prospective observational study enrolling patients with various cancers, and access information generated under this program.

[Read More]

Cancer Centers, biopharmaceuticals collaborate on precision medicines

Wednesday, April 20, 2016

M2Gen, a healthcare informatics solutions company, has announced a collaboration with pharmaceutical companies and the Oncology Research Information Exchange Network (ORIEN), an alliance of cancer centers throughout the U.S. M2Gen also announced that Celgene will be the industry’s founding member of a network of participants joining in this new initiative. The launch of the ORIEN Avatar Research Program brings together the pre-eminent players in healthcare R&D pharmaceutical companies and academic cancer centers to find new treatments for millions of Americans battling advanced-stage cancers.

[Read More]